bioMérieux S.A. (FRA:EYWN)

Market Cap	8.64B -33.2%
Revenue (ttm)	4.07B +2.3%
Net Income	397.50M -8.0%
EPS	3.34 -8.2%
Shares Out	n/a
PE Ratio	21.74
Forward PE	n/a
Dividend	0.98 (1.09%)
Ex-Dividend Date	Jun 9, 2026

Volume	n/a
Average Volume	n/a
Open	82.75
Previous Close	90.25
Day's Range	82.75 - 82.75
52-Week Range	82.75 - 130.60
Beta	n/a
RSI	31.44
Earnings Date	Jul 28, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1963
• Employees: 14,894
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EYWN

Financial Performance

In 2025, bioMérieux's revenue was 4.07 billion, an increase of 2.26% compared to the previous year's 3.98 billion. Earnings were 397.50 million, a decrease of -8.03%.